Obesity and BMI — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive guidance for coding obesity, overweight, and body mass index (BMI) conditions under FY2026 ICD-10-CM (effective October 1, 2025 – September 30, 2026). Obesity is among the most consequential diagnoses in risk adjustment, HCC capture, and chronic disease management. Accurate documentation and code selection from the E66.xx category — combined with supporting Z68.xx BMI codes — directly affects reimbursement, quality metrics, and RAF scores. This guide covers every facet of the documentation and coding encounter, from CDI query triggers and GLP-1 medication coding to HCC v28 mapping and complication sequencing.

🔍 1. Definition

Obesity is a chronic, complex metabolic disease characterized by excess body fat accumulation to the extent that it poses a risk to health. According to the World Health Organization (WHO), obesity is defined in adults as a Body Mass Index (BMI) ≥30.0 kg/m², and overweight as a BMI of 25.0–29.9 kg/m². The CDC reaffirms these thresholds and notes that BMI is a screening tool — not a diagnostic measure of body fatness — but is widely used clinically due to its ease of calculation.

Body Mass Index (BMI) is calculated as weight in kilograms divided by height in meters squared (kg/m²). BMI is documented by clinicians, nurses, and nutritionists, and is captured in ICD-10-CM as a Z68.xx secondary code when paired with a physician-documented obesity or overweight diagnosis. Per CMS guidelines, BMI codes are secondary diagnoses only and must be supported by a physician’s documentation of the associated condition.

Obesity classes (adult, per NHLBI):

• Class 1 obesity: BMI 30.0–34.9
• Class 2 obesity: BMI 35.0–39.9
• Class 3 obesity (morbid/severe): BMI ≥40.0

Pediatric obesity is defined differently. For children and adolescents aged 2–20, the CDC uses BMI-for-age percentile rather than absolute BMI values. Obesity is defined as BMI at or above the 95th percentile for age and sex; overweight is 85th to below the 95th percentile.

Obesity is recognized as a chronic disease by the Obesity Medicine Association (OMA), the American Medical Association (AMA), and other major medical societies. Its prevalence in the United States is approximately 41.9% of adults (CDC, 2024), making it one of the most frequently encountered diagnoses in inpatient, outpatient, and value-based care settings.

🗂️ 2. Alternative Terminology

Documentation may use various clinical, colloquial, or historical terms for obesity and related conditions. The table below maps common terms to their ICD-10-CM coding context.

🩺 3. Signs & Symptoms

Obesity is a clinical diagnosis requiring physician documentation for ICD-10-CM code assignment. While BMI measurement is objective, the following signs and symptoms prompt physician evaluation and CDI query opportunities:

• Anthropometric: BMI ≥30 kg/m² (adult); waist circumference >88 cm (women) or >102 cm (men) indicating central adiposity per NHLBI
• Respiratory: Exertional dyspnea, daytime hypersomnia, snoring, witnessed apneas, orthopnea — suggesting OSA (G47.33) or OHS (E66.2)
• Cardiovascular: Hypertension (I10), dyslipidemia (E78.xx), peripheral edema
• Musculoskeletal: Bilateral knee/hip pain, reduced range of motion — suggests osteoarthritis (M17.x, M16.x) secondary to obesity loading
• Metabolic: Fasting hyperglycemia, insulin resistance, acanthosis nigricans — suggestive of DM2 (E11.xx) or metabolic syndrome (E88.81)
• Gastrointestinal: Right upper quadrant discomfort, elevated LFTs — suggesting NAFLD/MASLD (K76.0) or NASH (K75.81)
• Genitourinary: Stress urinary incontinence (N39.3), urge incontinence (N39.41)
• Psychiatric/behavioral: Depression, binge eating patterns — may indicate binge eating disorder (F50.81)
• Dermatologic: Intertrigo, skin tags, stretch marks; in pediatric patients, increased adiposity with early puberty

🧭 4. Differential Diagnosis

Several conditions may mimic or co-exist with obesity or overweight. CDI specialists should ensure the physician has considered and documented these distinctions when appropriate.

📋 5. Clinical Indicators for Coders/CDI

The following chart elements serve as triggers for documentation review, CDI queries, and code assignment. Every indicator should be cross-referenced against physician documentation before a code is assigned.

🦴 6. Anatomy & Pathophysiology

Understanding the pathophysiology of obesity supports accurate CDI query formulation and complication coding. Obesity is a multisystem disease with complex neuroendocrine, metabolic, and mechanical mechanisms.

Energy Balance Dysregulation

Obesity develops when caloric intake chronically exceeds energy expenditure. Central regulation involves the hypothalamic-pituitary axis, leptin signaling, and ghrelin. Leptin resistance — where the hypothalamus no longer responds appropriately to adipokine signals — is a hallmark of established obesity, as described in StatPearls (NCBI). The incretin hormones GLP-1 and GIP (targeted by semaglutide and tirzepatide respectively) regulate postprandial insulin secretion and suppress appetite via central mechanisms — forming the basis of GLP-1 receptor agonist pharmacotherapy.

Adipose Tissue and Inflammation

Excess adipose tissue — particularly visceral adiposity — functions as an endocrine organ, secreting pro-inflammatory cytokines (TNF-α, IL-6) and adipokines. This chronic low-grade inflammation drives insulin resistance, dyslipidemia, and cardiovascular risk. Visceral adiposity is more metabolically harmful than subcutaneous fat, explaining why waist circumference and body fat distribution matter clinically beyond BMI alone.

Respiratory Pathophysiology (OHS)

In obesity hypoventilation syndrome (E66.2), excess thoracic and abdominal adipose tissue reduces chest wall compliance and lung volumes (reduced FRC, ERV). This leads to alveolar hypoventilation, hypercapnia (PaCO2 >45 mmHg), and hypoxemia. When combined with obstructive sleep apnea (G47.33), the resulting condition — OHS — is a distinct, more severe diagnosis than OSA alone. Chronic hypercapnia may progress to chronic respiratory failure (J96.1x), creating a HCC-additive coding scenario per PMID 33739115 (OHS Review).

Mechanical Complications

Excess body weight creates abnormal mechanical loading on weight-bearing joints. The knee joint experiences approximately 4× the force increase per pound of excess weight, accelerating cartilage degradation and driving osteoarthritis (M17.x). Hip OA (M16.x) is also significantly elevated. Increased intra-abdominal pressure contributes to stress urinary incontinence (N39.3) and GERD.

Hepatic and Metabolic Effects

Excess caloric intake and insulin resistance drive hepatic lipid accumulation, producing metabolic-associated steatotic liver disease (MASLD, formerly NAFLD — K76.0). Progression to NASH (K75.81) involves hepatic inflammation and fibrosis. The metabolic syndrome constellation (E88.81) — abdominal obesity, hypertriglyceridemia, low HDL, hypertension, and elevated fasting glucose — frequently co-occurs with obesity and compounds cardiovascular risk.

💊 7. Medication Impact / Treatment

Pharmacotherapy for obesity has undergone a paradigm shift with the approval and widespread adoption of GLP-1 receptor agonists. Accurate medication coding — particularly for long-term use — is critical for FY2024+ encounters and beyond.

GLP-1 Receptor Agonists (Critical FY2024+ Coding)

GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1, suppressing appetite centrally and slowing gastric emptying. They are now FDA-approved for both type 2 diabetes management and chronic weight management as distinct indications with different dosing regimens:

Other Pharmacotherapy

• Orlistat (Xenical, Alli): Lipase inhibitor reducing dietary fat absorption; GI side effects; available OTC/Rx
• Phentermine/topiramate (Qsymia): Sympathomimetic + anticonvulsant combination; appetite suppression
• Naltrexone/bupropion (Contrave): Opioid antagonist + antidepressant; acts on reward circuitry
• Setmelanotide (Imcivree): MC4R agonist for genetic obesity (LEPR, POMC deficiencies)
• SGLT2 inhibitors (empagliflozin, dapagliflozin): Not FDA-approved for obesity alone but cause weight loss; Z79.84 for long-term oral hypoglycemic use

Drug-Induced Obesity (E66.1)

Medications that commonly cause iatrogenic weight gain include: antipsychotics (olanzapine, clozapine, quetiapine), corticosteroids (E66.1 + adverse effect T code), insulin, certain antidepressants (tricyclics, mirtazapine), valproic acid, and lithium. When drug-induced obesity is documented, code E66.1 plus the appropriate adverse effect code from T36–T50 with 5th/6th character “A” (initial encounter), “D” (subsequent), or “S” (sequela).

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 8. ICD-10-CM Guidelines (FY2026)

The following guidelines govern obesity and BMI coding under FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (CMS/NCHS).

Guideline I.C.21.c.3 — Reporting of BMI

• BMI codes (Z68.xx) are secondary diagnoses only. They may never be a principal or first-listed diagnosis.
• BMI codes should only be reported when the encounter involves a condition that is related to the BMI, such as obesity, overweight, or underweight.
• “BMI codes and other categories of Z codes (Z68, Z86.3 etc.) may be used as a secondary code when the associated diagnosis is documented.”
• A BMI reported by a nutritionist or registered nurse may be used if the diagnosis of obesity, overweight, or underweight is documented by the responsible physician.
• Do not report a BMI code without a supporting physician-documented diagnosis (obesity, overweight, or underweight).

Guideline I.C.4 — Endocrine, Nutritional, and Metabolic Diseases (E00–E89)

• Obesity codes require physician documentation. Coders may not infer obesity solely from BMI values.
• When obesity complicates a procedure or other diagnosis, it should be coded as an additional diagnosis.
• Drug-induced obesity (E66.1) requires identification of the causative drug and coding of the adverse effect.

Complication Sequencing

• When obesity is the reason for the encounter (e.g., obesity management, bariatric consult), E66.xx is the principal/first-listed diagnosis.
• When a complication of obesity (e.g., OA knee, HTN, DM2) is the reason for the encounter, the complication is principal and E66.xx is secondary.
• For obstetric encounters: O99.21x (obesity complicating pregnancy) is sequenced using obstetric coding rules; E66.xx added for type specificity.
• BMI ≥40 documented in chart + physician’s documentation of obesity = assign both E66.01/E66.813 AND the appropriate Z68.4x code.

Bariatric Surgery and Post-Procedural Coding

• Z98.84 (bariatric surgery status) is reported as a secondary code at any subsequent encounter when the history is clinically relevant.
• Post-bariatric complications (dumping syndrome, malabsorption, vitamin deficiency, IDA) are coded as they occur with Z98.84 and the underlying obesity diagnosis if still clinically relevant.
• Nutritional deficiencies post-bariatric surgery (E55.9 vitamin D, D50.0 IDA) are coded as separate diagnoses when documented.

🔢 9. ICD-10-CM Code Set (FY2026)

E66 — Overweight and Obesity

Z68 — BMI Codes (Adult, Secondary Only)

Z68.5x — Pediatric BMI Codes (Age 2–20, Percentile-Based)

Related / Comorbidity Codes

🔎 10. Indexing

Coders should reference the FY2026 ICD-10-CM Tabular and Alphabetic Index (CMS) for the following main terms and subterms:

🏥 11. CPT (2026)

CPT codes applicable to obesity management, behavioral counseling, medical nutrition therapy (MNT), and bariatric surgery — all per AMA CPT 2026.

Preventive Counseling & Behavioral Interventions

Medical Nutrition Therapy (MNT)

Bariatric / Metabolic Surgery

🧾 12. HCPCS (2026)

📚 13. AHA Coding Clinic (Recent Guidance)

The following represents coding guidance and principles from AHA Coding Clinic relevant to obesity and BMI coding. Coders should verify current edition access for full text.

💰 14. HCC / Risk Adjustment (v28)

Obesity has significant risk adjustment implications under the CMS-HCC Model v28 used for Medicare Advantage plan payments (fully implemented 2024–2026 blend). Accurate HCC capture for obesity codes is one of the most impactful single-diagnosis RAF opportunities in chronic disease management.

✍️ 15. CDI Query Templates

All CDI query templates below are compliant with ACDIS and AHIMA standards: non-leading, multiple-choice format, with clinically neutral phrasing. Queries must be based on clinical indicators in the record.

🧑‍⚕️ 16. Treatments (Clinical)

Clinical treatment of obesity follows a stepwise, multimodal approach. CDI specialists should be aware of treatment context to accurately code encounters and identify documentation gaps.

Lifestyle Interventions (First-Line)

• Dietary modification: Caloric restriction, specific dietary patterns (Mediterranean, low-carbohydrate, DASH). Captured via Z71.3 (dietary counseling) and MNT CPT codes (97802–97804).
• Physical activity: 150–300 min/week moderate-intensity; resistance training. Coded as Z71.82 (exercise counseling) when documented.
• Behavioral therapy: CBT, motivational interviewing, structured weight-loss programs. G0447 (Medicare IBT) or 99401–99404 (preventive counseling).

Pharmacotherapy (Second-Line)

Indicated when BMI ≥30 (or ≥27 with comorbidity) and lifestyle modification alone is insufficient. GLP-1 receptor agonists have become the dominant pharmacotherapy class since 2021–2023 FDA approvals. See Section 7 for full medication coding guidance. Long-term medication use coded with Z79.85 (GLP-1 injectable) or Z79.84 (SGLT2 oral).

Metabolic/Bariatric Surgery (Third-Line)

Indicated for BMI ≥40 or BMI ≥35 with obesity-related comorbidities (DM2, HTN, OSA, OA). Per ASMBS guidelines, surgery is now considered for BMI ≥30–35 with metabolic disease in select patients. Common procedures:

• Sleeve gastrectomy (43775): Most performed; ~25% EBWL; purely restrictive; lower complication rate
• Roux-en-Y gastric bypass (43644): ~30–35% EBWL; best for GERD, DM2 remission; restrictive + malabsorptive
• Duodenal switch with biliopancreatic diversion (43845): Highest weight loss (~40% EBWL); highest nutritional risk; most malabsorptive
• Adjustable gastric band (43770): Largely abandoned due to lower efficacy and high revision rate; Z98.84 for band history

Endoscopic Bariatric Therapies (Emerging)

• Intragastric balloon: Temporary (6 months); coded with 43999 (unlisted)
• Endoscopic sleeve gastroplasty: Endoscopic suturing reducing gastric volume; 43499 or 43999
• Aspiration therapy: Largely discontinued post-FDA action

Obesity-Related Complication Management

Treatment of comorbidities is integral to obesity management and generates additional coding opportunities:

• OSA treatment: CPAP therapy (E0601 HCPCS); procedure code 95800 polysomnography
• HTN, DM2: Chronic disease management (chronic care management CPT 99490–99491)
• Joint replacement: TKA (27447), THA (27130) when OA is end-stage

🎓 17. Patient Education / Summary

This section provides clinician-facing patient education context. CDI specialists can use these talking points to understand what patients are being counseled on, which helps identify missing documentation that should be queried.

Key Patient Education Topics in Obesity Management

• Understanding BMI and body weight: BMI is a screening tool — not a perfect measure of health. A BMI ≥30 is associated with increased health risk, but individual clinical evaluation by a physician determines the diagnosis. Per CDC patient resources, treatment goals should be realistic (5–10% weight loss produces significant health benefits).
• Obesity is a chronic disease: The American Medical Association and Obesity Medicine Association classify obesity as a chronic disease requiring ongoing medical management — not a lifestyle choice or personal failing. This recognition supports appropriate ICD-10-CM diagnosis coding and insurance coverage for treatment.
• GLP-1 medications: Patients prescribed Wegovy (semaglutide), Zepbound (tirzepatide), or Saxenda (liraglutide) should understand these are long-term medications. Stopping treatment typically leads to weight regain. Documentation of GLP-1 therapy supports Z79.85 code assignment.
• Before bariatric surgery: Multi-disciplinary evaluation required including psychiatric screening, nutritional assessment, and medical clearance. Coding implication: multiple encounter types generate distinct codes (E66.01, dietary counseling Z71.3, pre-op clearance codes).
• Post-bariatric nutrition: Patients must take lifelong vitamin and mineral supplements post-bariatric surgery to prevent E55.9 (vitamin D), D50.0 (IDA), B12 deficiency, and calcium deficiency. Documentation of these deficiencies should trigger coding of E55.9, D50.0, etc., with Z98.84.
• Obesity comorbidities: Patients should understand that treating obesity can improve or resolve DM2, HTN, OSA, and joint pain. When these comorbidities resolve or improve, documentation should reflect the change (code the resolved condition with appropriate Z codes, or continue coding the chronic condition if still clinically present).
• Children and adolescents: Pediatric obesity (BMI ≥95th percentile for age/sex = Z68.54) requires family-based treatment. Physician documentation of the pediatric obesity diagnosis is required for ICD-10-CM code assignment beyond the Z68.54 BMI code.

Documentation Summary for CDI — Obesity Encounter Checklist

For additional guidance on obesity coding, refer to the FY2026 ICD-10-CM Official Guidelines (CMS), the AHA Coding Clinic, and the American Society for Metabolic and Bariatric Surgery (ASMBS) clinical guidelines.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)